FERNANDO GARCIA SADA – Trademark Portfolio
Entity Type: 01
FERNANDO GARCIA SADA holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 2 filings in this category. The portfolio also extends into Class 9 (Computers & Electronics) across 4 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include GUUD and SILTI.
CALZADA DEL VALLE NUM. EXT. 202,
NUM. INT. PISO 3, COLONIA DEL VALLE 66220 MONTERREY, NUEVO LEON
Showing of trademarks Trademarks
Trademark Classifications
FERNANDO GARCIA SADA's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does FERNANDO GARCIA SADA have?
FERNANDO GARCIA SADA has 2 U.S. trademarks filed with the USPTO. Of these, 2 registered.
What trademark classes does FERNANDO GARCIA SADA file in?
FERNANDO GARCIA SADA files trademarks across 4 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus), Class 44 (Medical Services). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are FERNANDO GARCIA SADA's most well-known trademarks?
FERNANDO GARCIA SADA's registered trademark portfolio includes well-known marks such as GUUD and SILTI. These are among 2 currently registered trademarks in the portfolio.
What is FERNANDO GARCIA SADA's trademark registration success rate?
FERNANDO GARCIA SADA has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.